The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

Ryan Brown; Rebekah Bennett; Clare Crean; Andrew Hindley; Julie McGimpsey; Nicholas Cunningham; Aaron Niblock; Suzanne McPherson; Kathryn Boyd; Allister Foy; Ciaren Graham; Graeme Greenfield; Mary Frances McMullin; Mark A. Catherwood

doi:10.1111/bjh.70198

The impact of JAK2^V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

Ryan Brown
, Rebekah Bennett
, Clare Crean
, Andrew Hindley
, Julie McGimpsey
, Nicholas Cunningham
, Aaron Niblock
, Suzanne McPherson
, Kathryn Boyd
, Allister Foy
, Ciaren Graham
, Graeme Greenfield
, Mary Frances McMullin^*
, Mark A. Catherwood

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

25 Downloads (Pure)

Abstract

Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2^V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2^V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).

Original language	English
Pages (from-to)	2597-2601
Number of pages	5
Journal	British Journal of Haematology
Volume	207
Issue number	6
Early online date	24 Oct 2025
DOIs	https://doi.org/10.1111/bjh.70198
Publication status	Published - Dec 2025

Keywords

JAK2
myeloproliferative neoplasm
pegylated interferon alpha

Access to Document

10.1111/bjh.70198Licence: CC BY

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation
Copyright 2025 The Authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 703 KBLicence: CC BY

Cite this

Brown, R., Bennett, R., Crean, C., Hindley, A., McGimpsey, J., Cunningham, N., Niblock, A., McPherson, S., Boyd, K., Foy, A., Graham, C., Greenfield, G., McMullin, M. F., & Catherwood, M. A. (2025). The impact of JAK2^V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. British Journal of Haematology, 207(6), 2597-2601. https://doi.org/10.1111/bjh.70198

@article{c9dbe9e2e73d4b62829f6b85e50ad678,

title = "The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation",

abstract = "Treatment with pegylated interferon α resulted in a molecular response in 91\% of patients with an average decrease in JAK2V61F VAF of 48.5\% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/). ",

keywords = "JAK2, myeloproliferative neoplasm, pegylated interferon alpha",

author = "Ryan Brown and Rebekah Bennett and Clare Crean and Andrew Hindley and Julie McGimpsey and Nicholas Cunningham and Aaron Niblock and Suzanne McPherson and Kathryn Boyd and Allister Foy and Ciaren Graham and Graeme Greenfield and McMullin, \{Mary Frances\} and Catherwood, \{Mark A.\}",

year = "2025",

month = dec,

doi = "10.1111/bjh.70198",

language = "English",

volume = "207",

pages = "2597--2601",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "6",

}

Brown, R, Bennett, R, Crean, C, Hindley, A, McGimpsey, J, Cunningham, N, Niblock, A, McPherson, S, Boyd, K, Foy, A, Graham, C , Greenfield, G, McMullin, MF & Catherwood, MA 2025, 'The impact of JAK2^V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation', British Journal of Haematology, vol. 207, no. 6, pp. 2597-2601. https://doi.org/10.1111/bjh.70198

TY - JOUR

T1 - The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

AU - Brown, Ryan

AU - Bennett, Rebekah

AU - Crean, Clare

AU - Hindley, Andrew

AU - McGimpsey, Julie

AU - Cunningham, Nicholas

AU - Niblock, Aaron

AU - McPherson, Suzanne

AU - Boyd, Kathryn

AU - Foy, Allister

AU - Graham, Ciaren

AU - Greenfield, Graeme

AU - McMullin, Mary Frances

AU - Catherwood, Mark A.

PY - 2025/12

Y1 - 2025/12

N2 - Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).

AB - Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).

KW - JAK2

KW - myeloproliferative neoplasm

KW - pegylated interferon alpha

U2 - 10.1111/bjh.70198

DO - 10.1111/bjh.70198

M3 - Article

C2 - 41132056

SN - 0007-1048

VL - 207

SP - 2597

EP - 2601

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -